Tagworks Pharmaceuticals has received CTA approval for the Phase 0/1 CleavHER trial of TGW211, a first-in-class HER2-directed radioimmunoconjugate developed with its Click-to-Release platform. Sponsored by Radboud University Medical Center, the study will evaluate safety, pharmacokinetics, and dosimetry in HER2-positive solid tumors, with first patient enrollment expected by the end of …

Tagworks Pharmaceuticals announces progress in its Phase 1 clinical trial of TGW101, a first-in-class antibody-drug conjugate (ADC) targeting TAG-72 in patients with advanced solid tumors. Following favorable safety reviews, the study has moved to the third dose level. Preliminary safety, pharmacokinetics, and early efficacy data are expected in early to …

We’re proud to share that Nature Biotechnology has published a new article featuring an interview with our CEO, Marc Robillard. The article includes a dedicated section on Tagworks, beginning on page three and continuing into page four. We invite you to read the full article via this link.

On June 19th, 2025, Marc Robillard will give a presentation about Tagworks’ Click-to-Release platform for ADCs and targeted radiotherapies at the Johnson & Johnson R&D Symposium on Antibody Conjugates in Beerse, Belgium. At this symposium exciting advancements in discovery and development of antibody-drug conjugates and targeted radiotherapies are explored by …

Tagworks initiates Phase 1 trial for TGW101, a first-in-class Click-to-Release ADC targeting TAG-72, and appoints Dr. Keith Orford as Chief Medical Officer.

Tagworks to present preclinical data demonstrating potential of its Click-to-Release platform to enable safe, tolerable, and potent delivery of therapeutic candidates for solid tumors

Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug conjugate (ADC) program for solid tumors into the clinic in 2025

We are excited to announce a recent addition to our rapidly expanding team: Krisztina Nemenyi has joined as our Vice President Regulatory Affairs.

A Dutch-American biotech is out with $65 million in Series A funding to get into the clinic with what it calls an expanded scope of the popular antibody-drug conjugates class after a decade of legwork iterating on the original click chemistry findings that led to last year’s Nobel Prize.

Read the article on Biopharmadive